UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
|
Date of Report (Date of earliest event reported): November 16, 2026 |
INOGEN, INC.
(Exact name of Registrant as Specified in Its Charter)
|
|
|
|
|
Delaware |
001-36309 |
33-0989359 |
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
|
|
|
|
|
500 Cummings Center Suite 2800 |
|
Beverly, Massachusetts |
|
01915 |
(Address of Principal Executive Offices) |
|
(Zip Code) |
|
Registrant’s Telephone Number, Including Area Code: (805) 562-0500 |
(Former address)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
Title of each class
|
|
Trading Symbol(s) |
|
Name of each exchange on which registered
|
Common Stock, $0.001 par value |
|
INGN |
|
The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Kevin R.M. Smith Separation Agreement; Resignation as a Director
As previously reported in the Current Report on Form 8-K filed by Inogen, Inc. (the “Company”), on November 5, 2026, Kevin R.M. Smith’s role as an officer and employee of the Company ended effective October 30, 2026 (the “Separation Date”). In connection with the separation of Mr. Smith’s employment with the Company, on November 16, 2026, Mr. Smith and the Company entered into a separation agreement and release related to the termination of Mr. Smith’s employment with the Company (the “Separation Agreement”).
The Separation Agreement provides that, subject to (a) Mr. Smith’s execution of the Separation Agreement, (b) the Separation Agreement becoming effective and (c) Mr. Smith’s continued compliance with the terms of the Separation Agreement, the Company will provide Mr. Smith with severance benefits consistent with those set forth in Mr. Smith’s Employment and Severance Agreement with the Company, effective as of November 10, 2023. The Separation Agreement also provides for Mr. Smith’s eligibility to earn a prorated annual bonus for fiscal 2026 based on actual performance and the vesting of certain equity awards that were scheduled to vest on December 1, 2026.
Also in connection with the separation of his employment with the Company and the entry into the Separation Agreement, Mr. Smith resigned from the Company’s board of directors (the "Board"), effective as of November 16, 2026. Mr. Smith’s resignation was not the result of any disagreement with the Company relating to the Company’s operations, policies or practices. Following Mr. Smith’s resignation, the Board reduced the authorized number of directors from nine to eight, effective as of November 17, 2026.
The summary of the Separation Agreement set forth above does not purport to be complete and is qualified in its entirety by reference to the full text of the Separation Agreement, which is filed with this Current Report on Form 8-K as Exhibit 10.1 and incorporated by reference herein.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
The exhibits listed below are furnished or filed, as applicable, with this Current Report on Form 8-K:
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
|
|
|
|
|
|
INOGEN, INC. |
|
|
|
|
Date: |
November 19, 2026 |
By: |
/s/ Jason Richardson |
|
|
|
Jason Richardson Executive Vice President, Chief Financial Officer Treasurer (Principal Accounting and Financial Officer) |